日本厚生劳动省的一个专家小组已批准将住友制药的Amchepry纳入国家医疗保险覆盖范围，这是一种源自iPS细胞的帕金森病治疗药物。此举使其成为全球首个商业化的iPS细胞医疗产品。
该项批准来自日本厚生劳动省下属的一个专家小组，涵盖了住友制药用于治疗帕金森病的Amchepry。
Amchepry由诱导多能干细胞制成。这一决定确立了该产品作为全球首个实现商业化的此类疗法的地位。
该专家小组的行动为患者通过日本国家医疗保健系统获得更广泛的治疗扫清了障碍。
由 AI 报道 AI 生成的图像
A health ministry expert panel has conditionally approved two regenerative medicine products derived from induced pluripotent stem (iPS) cells for treating Parkinson's disease and severe heart disease. This marks a potential world first in commercializing Nobel Prize-winning stem cell technology. The approval, based on small-scale clinical trials confirming safety and presumed efficacy, requires post-market verification within seven years.
Following an expert panel's recommendation last month, Japan's Health, Labor and Welfare Ministry on March 6 conditionally approved two iPS cell-derived regenerative medicines—the world's first commercialized such treatments—for severe heart failure and Parkinson's disease. The products carry conditions and time limits, with pricing and insurance coverage decisions next; sales could begin as early as summer 2026.
由 AI 报道
Japan's health ministry panel on Thursday approved the commercialization of two regenerative medicine products derived from iPS cells, marking a global first. These treatments target patients with severe heart failure and Parkinson's disease, under a conditional approval requiring data collection for up to seven years. Shinya Yamanaka, pioneer of iPS cell research, expressed delight at this milestone.
Sequencio, a new Hong Kong unit of CK Life Sciences, is advancing about 20 cancer vaccine projects via China's faster pathway to human trials. CK Life Sciences vice-president and chief scientific officer Dr Melvin Toh Kean-meng said the firm plans investigator-initiated trials next year.
由 AI 报道
PhilHealth has expanded its Z Benefits Package to cover at least 10 rare genetic conditions. The benefits include case rates ranging from roughly P99,000 to P739,000. This move supports ongoing efforts to improve care for rare disease patients in the Philippines.